SCHEMBL6485937

SCHEMBL6485937

CN(C)S(=O)(=O)c1c[nH]c2c(Cl)cccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 2/20 0.47
▸ NR4A2 P43354 1/20 0.46
▸ DYRK1A Q13627 3/20 0.44
▸ HTR2A P28223 1/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA3 P07451 1/20 0.41
▸ CA6 P23280 1/20 0.41
▸ CA5A P35218 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ CA5B Q9Y2D0 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PKM P14618 1/20 0.39
▸ RIPK1 Q13546 3/20 0.39
▸ TDO2 P48775 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5730144 0.82 NR4A2 (0.49) SLC6A4NR4A2DYRK1AHTR2ACA12
SCHEMBL26980813 0.80 DYRK1A (0.49) SLC6A4NR4A2DYRK1AHTR2ACA12
SCHEMBL6478098 0.79 NR4A2 (0.49) SLC6A4NR4A2DYRK1AHTR2ACA12
SCHEMBL17442030 0.75 CYP1A2 (0.48) ALDH1A1SMN1; SMN2PKMMCOLN3
SCHEMBL5730432 0.73 MEN1 (0.47) SLC6A4HTR2AALDH1A1SMN1; SMN2PKM
SCHEMBL2642338 0.71 MCOLN3 (0.67) ALDH1A1SMN1; SMN2MCOLN3
SCHEMBL2229460 0.70 PGR (0.54) HTR2AALDH1A1SMN1; SMN2MCOLN3
SCHEMBL28094190 0.70 MET (0.61) SLC6A4DYRK1A
SCHEMBL28251367 0.69 DYRK1A (0.60) SLC6A4NR4A2DYRK1AHTR2ACA12
SCHEMBL5729731 0.69 POLB (0.52) SLC6A4NR4A2HTR2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852726-B2 Substituted indoles as alpha-1 agonists SYNTEX LLC (US) 2005-02-08 — — US disclosed
US-20030220319-A1 Substituted indoles as alpha-1 agonists SYNTEX (U.S.A.) LLC 2003-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220319-A1 Substituted indoles as alpha-1 agonists ADRA1A, ADRB1, ADRA1B SLC6A4 440/4885NR4A2 230/4885DYRK1A 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback